Updating results

492 results

Sort: Relevance | Date

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: TBC

Technology appraisal guidance In development

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: 18 November 2020

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Avelumab for untreated PD-L1 positive non-small-cell lung cancer [ID1261]

In development [GID-TA10250] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab for multiple myeloma [ID966]

In development [GID-TA10134] Expected publication date: TBC

Technology appraisal guidance In development

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: TBC

Technology appraisal guidance In development

Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

In development [GID-TA10607] Expected publication date: TBC

Technology appraisal guidance In development

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]

In development [GID-TA10181] Expected publication date: TBC

Technology appraisal guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: TBC

Technology appraisal guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma [ID2708]

In development [GID-TA10588] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]

In development [GID-TA10400] Expected publication date: TBC

Technology appraisal guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance In development

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

In development [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

In development [GID-TA10589] Expected publication date: TBC

Technology appraisal guidance In development

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

In development [GID-TA10573] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

In development [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

In development [GID-TA10581] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

In development [GID-TA10583] Expected publication date: TBC

Technology appraisal guidance In development

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance In development

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

In development [GID-TA10568] Expected publication date: TBC

Technology appraisal guidance In development

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: TBC

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Technology appraisal guidance In development

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

In development [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development